Feedback / Questions
VTx-002 - VectorY
https://www.businesswire.com/news/home/20251203338299/en/VectorY-Therapeutics-Receives-FDA-Clearance-of-IND-to-Proceed-with-the-PIONEER-ALS-Phase-12-Trial-of-VTx-002-a-First-in-Class-Vectorized-Antibody-Targeting-TDP-43-Pathology-in-ALS
Dec 3, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next